AGIO Reports Phase 1/2 Clinical Trial Of AG-221; PSTI Advances Its Second Major Cell Therapy Product Line
October 22, 2014 at 04:24 AM EDT
Agios Pharmaceuticals announced the initiation of a Phase 1/2 multicenter study of AG-221 in patients with advanced solid tumors. Pluristem Therapeutics announced it has completed development of its second major product line.
